A cloud-based digital pathology platform has helped a CRO deliver more informed preclinical studies.
Proscia announced that Virscio, a provider of translational research and development services, has deployed Concentriq for Research.
90% of drug candidates fail during clinical trials.1 This negatively impacts R&D efficiency, as measured by the number of new drugs approved relative to investment. Effective preclinical development hinges on accurate and high throughput evaluation of large volumes of pathology data to define the safety of a candidate before it can move on to human clinical trials.
As such, Virscio recognised that optimising its pathology operations by adopting Concentriq for Research would enable its sponsors to more rapidly advance lead programmes and get therapeutic breakthroughs to patients sooner.
“We are excited to welcome Virscio to the growing roster of organisations turning to Concentriq for Research to accelerate therapeutic innovation,” said David West, Proscia’s Chief Executive Officer. “Virscio is driving forward a new era of preclinical development, and we look forward to seeing the impact of digital pathology in addressing the critical challenge of R&D efficiency.”
- Acta Pharmaceutica Sinica B. (2022, July) Why 90% of clinical drug development fails and how to improve it? Retrieved April 19, 2023, from https://doi.org/10.1016/j.apsb.2022.02.002